157 related articles for article (PubMed ID: 34191390)
21. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemistry-based subtyping of breast carcinoma in Egyptian women: a clinicopathologic study on 125 patients.
Elesawy BH; Abd El hafez A; Shawky Ael-A; Arafa M
Ann Diagn Pathol; 2014 Feb; 18(1):21-6. PubMed ID: 24321463
[TBL] [Abstract][Full Text] [Related]
23. AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.
Cao L; Xu C; Xiang G; Liu F; Liu X; Li C; Liu J; Meng Q; Jiao J; Niu Y
Mol Cancer; 2018 Sep; 17(1):136. PubMed ID: 30217192
[TBL] [Abstract][Full Text] [Related]
24. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.
Prat A; Carey LA; Adamo B; Vidal M; Tabernero J; Cortés J; Parker JS; Perou CM; Baselga J
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139534
[TBL] [Abstract][Full Text] [Related]
25.
Fararjeh AS; Liu YN
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database.
Vallejos CS; Gómez HL; Cruz WR; Pinto JA; Dyer RR; Velarde R; Suazo JF; Neciosup SP; León M; de la Cruz MA; Vigil CE
Clin Breast Cancer; 2010 Aug; 10(4):294-300. PubMed ID: 20705562
[TBL] [Abstract][Full Text] [Related]
27. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of PDEF factor expression and its relation to androgen receptor in ER
Cao L; Li C; Xu C; Xiang G; Liu F; Liu X; Jiao J; Lv S; Niu Y
Histopathology; 2018 Nov; 73(5):819-831. PubMed ID: 29969155
[TBL] [Abstract][Full Text] [Related]
29. Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women.
Crispo A; Montella M; Buono G; Grimaldi M; D'Aiuto M; Capasso I; Esposito E; Amore A; Nocerino F; Augustin LS; Giudice A; Di Bonito M; Giuliano M; Forestieri V; De Laurentiis M; Rinaldo M; Ciliberto G; De Placido S; Arpino G
Curr Res Transl Med; 2016; 64(1):15-20. PubMed ID: 27140595
[TBL] [Abstract][Full Text] [Related]
30. Expression of Protein 4.1 Family in Breast Cancer: Database Mining for 4.1 Family Members in Malignancies.
Feng G; Guo K; Yan Q; Ye Y; Shen M; Ruan S; Qiu S
Med Sci Monit; 2019 May; 25():3374-3389. PubMed ID: 31063460
[TBL] [Abstract][Full Text] [Related]
31. The transcription factor SPDEF suppresses prostate tumor metastasis.
Steffan JJ; Koul S; Meacham RB; Koul HK
J Biol Chem; 2012 Aug; 287(35):29968-78. PubMed ID: 22761428
[TBL] [Abstract][Full Text] [Related]
32. ETV7 regulates breast cancer stem-like cell features by repressing IFN-response genes.
Pezzè L; Meškytė EM; Forcato M; Pontalti S; Badowska KA; Rizzotto D; Skvortsova II; Bicciato S; Ciribilli Y
Cell Death Dis; 2021 Jul; 12(8):742. PubMed ID: 34315857
[TBL] [Abstract][Full Text] [Related]
33. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.
Sabatier R; Finetti P; Guille A; Adelaide J; Chaffanet M; Viens P; Birnbaum D; Bertucci F
Mol Cancer; 2014 Oct; 13():228. PubMed ID: 25277734
[TBL] [Abstract][Full Text] [Related]
34. Examination of methylation changes of
Shirkavand A; Boroujeni ZN; Aleyasin SA
Indian J Cancer; 2018; 55(4):366-371. PubMed ID: 30829272
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
36. Gene co-expression network approach for predicting prognostic microRNA biomarkers in different subtypes of breast cancer.
Adhami M; MotieGhader H; Haghdoost AA; Afshar RM; Sadeghi B
Genomics; 2020 Jan; 112(1):135-143. PubMed ID: 30735795
[TBL] [Abstract][Full Text] [Related]
37. Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups.
Yao K; Goldschmidt R; Turk M; Wesseling J; Stork-Sloots L; de Snoo F; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):81-8. PubMed ID: 26424167
[TBL] [Abstract][Full Text] [Related]
38. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer.
Kim GE; Lee JS; Choi YD; Lee KH; Lee JH; Nam JH; Choi C; Kim SS; Park MH; Yoon JH; Kweon SS
BMC Cancer; 2014 Dec; 14():959. PubMed ID: 25510449
[TBL] [Abstract][Full Text] [Related]
39. Behaviour of breast cancer molecular subtypes through tumour progression.
Castaneda CA; Andrés E; Barcena C; Gómez HL; Cortés-Funés H; Ciruelos E
Clin Transl Oncol; 2012 Jun; 14(6):481-5. PubMed ID: 22634538
[TBL] [Abstract][Full Text] [Related]
40. Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes.
Mesquita B; Lopes P; Rodrigues A; Pereira D; Afonso M; Leal C; Henrique R; Lind GE; Jerónimo C; Lothe RA; Teixeira MR
Breast Cancer Res Treat; 2013 Feb; 138(1):37-45. PubMed ID: 23329352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
